NAGE logo

NAGE
Niagen Bioscience Inc.

3,538
Mkt Cap
$336.34M
Volume
120.00
52W High
$14.69
52W Low
$4.16
PE Ratio
20.93
NAGE Fundamentals
Price
$4.28
Prev Close
$4.20
Open
$4.22
50D MA
$5.21
Beta
1.30
Avg. Volume
952,281.20
EPS (Annual)
$0.2034
P/B
4.46
Rev/Employee
$1.11M
$481.40
Loading...
Loading...
News
all
press releases
Niagen Bioscience, Inc. (NASDAQ:NAGE) Short Interest Down 13.6% in March
Niagen Bioscience, Inc. (NASDAQ:NAGE - Get Free Report) was the target of a large decrease in short interest in the month of March. As of March 13th, there was short interest totaling 5,578,868...
MarketBeat·2h ago
News Placeholder
More News
News Placeholder
Niagen Bioscience (NASDAQ:NAGE) Upgraded at Wall Street Zen
Wall Street Zen raised Niagen Bioscience from a "hold" rating to a "buy" rating in a research report on Saturday...
MarketBeat·3d ago
News Placeholder
Niagen Bioscience Increases Share Repurchase Program to $20 Million
Niagen Bioscience, Inc. (NASDAQ: NAGE), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the science of healthy aging, today announced that its Board of Directors has...
Business Wire·12d ago
News Placeholder
Niagen Bioscience Surpasses 300 External Research Agreements from Leading Global Institutions on Niagen, Contributing to 45 Published Clinical Studies
Niagen Bioscience, Inc. (NASDAQ: NAGE), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the science of healthy aging, today announced that its external research...
Business Wire·14d ago
News Placeholder
Niagen Bioscience Launches Niagen Skincare Innovation Lab and Debuts Dermatologist-Tested Niagen NanoCloud, From Tru Niagen Powered by Patented Niagen
Niagen Bioscience, Inc. (NASDAQ: NAGE), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the science of healthy aging, today announced the launch of Niagen Skincare...
Business Wire·21d ago
News Placeholder
HC Wainwright Issues Optimistic Outlook for NAGE Earnings
Niagen Bioscience, Inc. (NASDAQ:NAGE - Free Report) - HC Wainwright increased their Q1 2026 earnings estimates for shares of Niagen Bioscience in a report released on Thursday, March 5th. HC...
MarketBeat·25d ago
News Placeholder
Canaccord Genuity Group Cuts Niagen Bioscience (NASDAQ:NAGE) Price Target to $13.00
Canaccord Genuity Group dropped their price objective on Niagen Bioscience from $14.00 to $13.00 and set a "buy" rating for the company in a report on Thursday...
MarketBeat·26d ago
News Placeholder
Niagen Bioscience Rallies 18% After Hours: Here's Why
Niagen Bioscience Inc. surged in after-hours trading after reporting record 2025 results, while maintaining a cautious outlook for 2026.read more...
Benzinga·26d ago
News Placeholder
Niagen Bioscience Doubles Annual Profit, CEO Signals Acquisition Hunt And GLP-1-Style Expansion Stock Jumps After-Hours (UPDATED)
NAD+ company Niagen Bioscience doubles profits in 2025, eyes acquisitions and new markets as the longevity market picks up momentum.read more...
Benzinga·26d ago
News Placeholder
Niagen Bioscience (NAGE) Earnings Transcript
@media (max-width: 768px) { .image-container { width: 100% !important; float: none !important; margin: 0 0 1rem 0 !important; } } Image source: The Mo...
Nasdaq News: Markets·26d ago
<
1
2
...
>

Latest NAGE News

View
Top Discussions

Advertisement|Remove ads.

Advertisement|Remove ads.